Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-SSc: MMF Post-AHSCT for Systemic Sclerosis Relapse Prevention
NCT07734012Phase 2Not yet recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mycophenolate mofetil in systemic sclerosis (SSc) (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoints: Feasibility at 18 months, Efficacy at Day 270 and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07734012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07734012.